MacroLensNP नेपालीने Sign in Create accountSign up
Free · Life Insurance

CLI Citizen Life Insurance Company Limited

Rs 442.00 +1.50 (+0.34%) as of 2026-11-06 15:00:00
Open
439.00
High
445.00
Low
438.00
Prev. close
440.50
Volume
9,368
Turnover
41.41 lakh
Avg volume (30 d)
11,799
52-week low Rs 410.00
high Rs 526.00 -16.0% from the 52-week high

Citizen Life Insurance Company Limited (CLI) is listed on the Nepal Stock Exchange in the Life Insurance sector. Its share price is Rs 442.00 as of 6 November 2026, 16.0% below its 52-week high of Rs 526.00 and 7.8% above its 52-week low of Rs 410.00. It trades at a P/E of 56.5 on earnings per share of Rs 7.82, close to the Life Insurance sector's median P/E of 56.6.

CLI paid a dividend in 3 of the last 3 fiscal years we track; the latest was 20.00% cash for FY 2081/2082. Promoters hold 70% of the shares and the public 30%.

Key figures latest report 2082/2083 Q4

Market value
2,210 crore · 22.10 arba
Shares listed
50,000,000
Paid-up capital
500.00 crore · 5.00 arba
EPS (annualised)
Rs 7.82
P/E
56.5
Book value / share
Rs 131.60
P/B
3.36
ROE
7.9%
ROA
1.14%
Dividend yield
4.52%
Net profit (annualised)
39.08 crore
Reserves
–
Total assets
3,441 crore · 34.41 arba
Debt to equity
4.23

Quarter by quarter trailing 12 months at each quarter

QuarterEPSEPS growth (y/y)Net profitRevenueROE
2082/2083 Q4 7.82 -8.0% 39.08 crore 937.41 crore · 9.37 arba 5.7%
2082/2083 Q3 8.55 +6.6% 42.74 crore 868.55 crore · 8.69 arba 6.1%
2082/2083 Q2 8.51 -1.5% 42.56 crore 831.03 crore · 8.31 arba 6.0%
2082/2083 Q1 8.51 +10.8% 42.56 crore 803.36 crore · 8.03 arba 5.8%
2081/2082 Q4 8.50 +30.9% 42.50 crore 754.82 crore · 7.55 arba 5.9%
2081/2082 Q3 8.02 +7.0% 40.11 crore 705.41 crore · 7.05 arba 5.7%
2081/2082 Q2 8.64 +74.7% 43.21 crore 836.61 crore · 8.37 arba 6.2%
2081/2082 Q1 7.68 +34.4% 38.42 crore 645.88 crore · 6.46 arba 5.4%

Dividends

Fiscal yearBonusCashBook close
2081/2082– 20.00% 23 Dec 2025
2080/208126.98% 1.42% 12 Mar 2025
2079/20805.00% 0.26% 14 Jan 2024

Bonus / right shares: Mar 2025 Bonus share 27% · Jan 2024 Bonus share 5%

Who owns it

Promoters 70% Public 30%
Public float
15,000,000 shares
Mutual funds hold
4.9% of the float
Promoter lock-in
–

MacroLens analysis of CLI

More on CLI on the full desk The rating and verdict, fair value, dump risk and warning signs, the 12-month target, the buy / sell meter with every past signal, cornering and broker activity - the analysis behind every number above. Create an account - 7-day trial

Other Life Insurance companies

CompanyPriceTodayP/EP/BMarket value
NLIC Nepal Life Insurance Co. Ltd. 740.00 +0.14% 150.75.87 7,015 crore · 70.15 arba
LICN Life Insurance Co. Nepal 799.00 +0.26% 108.34.49 4,395 crore · 43.95 arba
NLICL National Life Insurance Co. Lt... 580.00 -0.17% 89.14.54 3,301 crore · 33.01 arba
HLI Himalayan Life Insurance Limit... 303.00 -0.10% 87.13.25 2,770 crore · 27.70 arba
RNLI Reliable Nepal Life Insurance... 446.00 -0.67% 39.83.00 2,318 crore · 23.18 arba
PMLI Prabhu Mahalaxmi Life Insuranc... 429.00 +0.37% 60.63.68 2,277 crore · 22.77 arba
ALICL Asian Life Insurance Co. Limit... 422.20 -0.42% 53.53.51 2,217 crore · 22.17 arba
ILI IME Life Insurance Company Lim... 443.00 +0.07% 37.93.27 2,215 crore · 22.15 arba

Every Life Insurance company 14

Browse all NEPSE stocks by sector →

CLI: common questions

What is the share price of CLI today?

CLI (Citizen Life Insurance Company Limited) closed at Rs 442.00 as of 6 November 2026 on NEPSE.

Does CLI pay dividends?

CLI paid a dividend in 3 of the last 3 fiscal years we track; the latest was 20.00% cash for FY 2081/2082.

What is the P/E ratio of CLI?

It trades at a P/E of 56.5 on earnings per share of Rs 7.82, close to the Life Insurance sector's median P/E of 56.6.

Is CLI a good buy?

This page is not buy or sell advice. MacroLens NP rates every NEPSE company on its fundamentals - CLI's rating, fair value, dump risk and broker activity are on the desk, free for 7 days.

Prices from NEPSE; figures from the company's quarterly reports; dividends, ownership and news from public filings. Research, not a recommendation to buy or sell - see the risk disclosure.